Xiao Hui Gu
Keine laufenden Positionen mehr
Karriereverlauf von Xiao Hui Gu
Ehemalige bekannte Positionen von Xiao Hui Gu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | 01.01.2008 | 01.01.2008 |
EXELIXIS, INC. | Corporate Officer/Principal | - | - |
PHARMARON BEIJING CO., LTD. | Corporate Officer/Principal | 01.05.2011 | - |
Ausbildung von Xiao Hui Gu
Hunan Normal University | Undergraduate Degree |
Shanghai Institute of Organic Chemistry | Doctorate Degree |
Statistik
International
China | 4 |
Vereinigte Staaten | 3 |
Operativ
Corporate Officer/Principal | 3 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sektoral
Commercial Services | 3 |
Consumer Services | 3 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
PHARMARON BEIJING CO., LTD. | Commercial Services |
EXELIXIS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
- Börse
- Insiders
- Xiao Hui Gu
- Erfahrung